Stock return since Jan. 1: 84%
I was on the fence about including Regeneron on this list until the stock strolled past $100 per share Monday. I get it -- Regeneron has a newly approved and launched eye drug, Eylea, that's requires fewer inconvenient, uncomfortable (creepy?) eye injections than Roche's Lucentis (and repurposed, off-label Avastin) for treating age-related macular degeneration. But Regeneron is now valued at well over $9 billion. Even if Eylea does really well and brings in $1 billion in sales (not a sure thing by any means), Regeneron's valuation is bubblicious. Regeneron is the new Vertex Pharmaceuticals (VRTX).Regeneron shares closed Tuesday down less than 1% to $100.34.